News

Home/News
News 2017-06-21T13:15:59+00:00
August 15, 2017
Onconova Therapeutics, Inc. Reports Recent Business Highlights and Second Quarter 2017 Financial Results
NEWTOWN, Pa., Aug. 15, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small ...
August 15, 2017
Aradigm Awarded NIH Grant to Investigate the Treatment of Pulmonary Non-Tuberculous Mycobacterial (PNTM) Infections with Linhaliq
HAYWARD, Calif. -- (BUSINESS WIRE) -- The National Institute of Allergy and Infectious Diseases (NIAID) and National Institutes of Health (NIH) awarded Aradigm Corporation (ARDM) a ...
August 15, 2017
VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for VBI-1901 to Treat Glioblastoma Multiforme
CAMBRIDGE, MASSACHUSETTS--(Marketwired - Aug 15, 2017) - VBI Vaccines Inc. (VBIV) (VBV.TO) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today ...
August 15, 2017
CymaBay Therapeutics Announces the Publication of the Seladelpar Proof-of-Concept Study for Primary Biliary Cholangitis in Lancet Gastroenterology and Hepatology
NEWARK, Calif., Aug. 15, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic ...
August 14, 2017
Gemphire Announces Second Quarter 2017 Financial Results and Provides Corporate Update
LIVONIA, Mich., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, ...
August 14, 2017
Prometic and Shenzhen Royal Asset Management Close Transaction for Joint Venture and Licensing Rights to PBI-4050, PBI-4547 and PBI-4425 in China
LAVAL, QC , Aug. 14, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) (Prometic) today announced that it has executed definitive agreements in relation ...
August 14, 2017
VBL Therapeutics Announces Second Quarter 2017 Financial Results
TEL AVIV, Israel, Aug. 14, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (VBLT), announced financial results for the three and six months ended June 30, 2017 ...
August 14, 2017
BioTime Announces $2 Million Grant for Further Development of OpRegen® for Dry-AMD
ALAMEDA, Calif. -- (BUSINESS WIRE) -- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, has been awarded ...
August 14, 2017
FDA Confirms That Use of mFARS as Primary Endpoint in Part 2 of the MOXIe Trial Can Support Approval of Omaveloxolone in Friedreich’s Ataxia
IRVING, Texas, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced that the U.S. ...
August 14, 2017
CytoSorbents Awarded $719,000 Grant To Acutely Stabilize Severe Burn Patients
MONMOUTH JUNCTION, N.J., Aug. 14, 2017 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a leader in critical care immunotherapy specializing in blood purification, announced that it has been ...
August 14, 2017
Eiger BioPharmaceuticals Reports Second Quarter 2017 Financial Results
PALO ALTO, Calif., Aug. 14, 2017 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today ...
August 14, 2017
Lipocine Announces FDA Acknowledgement of TLANDO™ (“LPCN 1021”) NDA Resubmission; PDUFA Goal Date, February 8, 2018
SALT LAKE CITY, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Lipocine Inc. (LPCN), a specialty pharmaceutical company, today announced that the U.S. Food & Drug Administration ...
August 14, 2017
Immune Pharmaceuticals Appoints Tony Fiorino, MD, PhD as Chief Medical Officer and Chief Operating Officer
NEW YORK -- (BUSINESS WIRE) -- Immune Pharmaceuticals (IMNP) (the “Immune” or the “Company”) announced today that it has appointed Tony Fiorino, MD, PhD to the ...
August 14, 2017
Rexahn Pharmaceuticals Issues Mid-Year Shareholder Letter to Review Recent Progress and Clinical Plans
ROCKVILLE, Md., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical-stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of ...
August 11, 2017
Alcobra Announces Second Quarter 2017 Financial Results and Provides Corporate Update
TEL AVIV, Israel, Aug. 11, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (ADHD) today announced financial results for the three and six months ended June 30, ...
August 11, 2017
AIT Therapeutics Reports Second Quarter 2017 Financial Results
REHOVOT, Israel and NEW YORK, Aug. 11, 2017 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (AITB), a clinical-stage anti-microbial therapeutic company treating respiratory diseases with nitric ...
August 10, 2017
Aurinia Reports Second Quarter 2017 Financial Results, and Provides Operational Highlights
VICTORIA, British Columbia -- (BUSINESS WIRE) -- Aurinia Pharmaceuticals Inc. (AUPH) (AUP.TO) (“Aurinia” or the “Company”) has released its financial results for the second quarter ended ...
August 10, 2017
CymaBay Reports Second Quarter 2017 Financial Results and Provides Corporate Update
NEWARK, Calif., Aug. 10, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic ...
August 10, 2017
STRATA Skin Sciences Reports Second Quarter 2017 Financial Results
HORSHAM, Pa., Aug. 10, 2017 (GLOBE NEWSWIRE) -- (SSKN) STRATA Skin Sciences, Inc. (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to ...
August 10, 2017
TherapeuticsMD Provides TX-004HR Regulatory Update
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women’s healthcare company, today announced a regulatory update regarding the New Drug Application (NDA) ...
Page 13 of 33